Investor Growth Equity Opportunities Fund III, LLC
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Growth Equity Opportunities Fund III, LLC . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2021-10-25 13D/A SBBP / Strongbridge Biopharma plc 4,141,308
2021-03-11 13D/A AUPH / Aurinia Pharmaceuticals Inc. 5,593,342
2017-01-09 13D AUPH / Aurinia Pharmaceuticals Inc. 3,183,553 5,593,342
2017-01-06 13D/A SBBP / Strongbridge Biopharma plc 2,141,308 4,141,308
2016-08-05 13D/A ILIU / Interleukin Genetics, Inc. 106,980,342
2016-05-18 13D/A SBBP / Strongbridge Biopharma plc 2,141,308
2015-02-11 13G AUPH / Aurinia Pharmaceuticals Inc. 3,183,553
2015-02-03 13G/A ALIM / Alimera Sciences, Inc.
2015-01-02 13D/A ILIU / Interleukin Genetics, Inc. 66,738,894
2013-05-24 13D ILIU / Interleukin Genetics, Inc. 22,719,382
2012-07-27 13G ALIM / Alimera Sciences, Inc. 2,681,250